Five Prime Therapeutics, Inc.

Accurus Biosciences, Inc.

Haishan Lin

Lewis T Williams

Stephen Kohl Doberstein

Kevin Hestir

Ernestine A Lee

Li Long

Shannon Marshall

Elizabeth Bosch

Cindy Leo

Ge Wu

Aileen Zhou

Justin G P Wong

Dirk Behrens

Robert Forgan Halenbeck

Min Mei Huang

Thomas Linnemann

Brian Wong

Yi Lin Zhang

Justin Wong

Emma Masteller

Minmei Huang

Richard Zhang

Justin G Wong

Steven Doberstein

Thomas Five Prime Therapeutics Inc Linnemann

Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN 18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibodies, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibodies, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.

CLDN 18.2-specific monoclonal antibodies and methods of use thereof

Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.

Blocking antibodies against CD47 and methods of use thereof

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.

Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules

The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).

Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules

Novel soluble Notch receptor ligands and polynucleotides encoding such are disclosed, as well as methods for producing and using these novel nucleotides and polypeptides. These novel polypeptides or agonists or antagonists thereto modulate cellular activity, regulate the growth and division of cell, including stem cells, progenitor and precursor cells, are involved in cell fate decisions, and provide prophylactic or therapeutic benefits for treatment of human diseases. Expression systems are provided that facilitate the production, secretion, and purification of these molecules.

Human soluble notch receptor ligands

Growing community of inventors

Moraga, CA, United States of America

Haishan Lin